01-novaseq x series 10B reagent kit (100 cycle) 02-novaseq x series 1.5B reagent kit (100 CYC) 03-nextseq 2000 P4 xleapsbs reagent kit (200 cycles) 04-nextseq 2000 P4 xleapsbs reagent kit (100 cycles)…
Ended Awarded
- Contract number
- 75N92B25F20013
- Awardee
-
Illumina, Inc. UEI KMW3CRWNAAF3
- Awarding agency
-
National Insititue of Arthritis and Musculoskeletal and Skin Diseases
National Institutes of Health, Department of Health and Human Services
- Obligated
- $98,243
Award facts
- Contract value 100% obligated
- $98,243.37 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 334516 Analytical Laboratory Instrument Manufacturing
- PSC
- 6640 Laboratory Equipment And Supplies
- Set-aside
- No set-aside
- Competition
- Not Competed Only One Source
- Pricing
- Firm Fixed Price
- Place of performance
- San Diego, CA 92122, USA
Award details come from SAM.gov/FPDS.
About this award
This federal contract award to Illumina, Inc., a biotechnology company specializing in genetic sequencing and genomic analysis technologies, is a Delivery Order with a Firm Fixed Price valued at $98,243.37. The award was made by the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), a civilian agency within the U.S. Department of Health and Human Services. The contract includes the provision of various Illumina sequencing reagent kits and library preparation products, such as the NovaSeq X, NextSeq 2000, and Illumina DNA PCR-Free Prep, Tagmentation. This contract does not have a set-aside designation. The award has an ultimate completion date of March 2, 2026. Illumina holds several other significant federal Indefinite Delivery Vehicles (IDVs), including a $45 million contract with the U.S. Department of Agriculture (USDA) and a $231,165 Blanket Purchase Agreement with the Department of Veterans Affairs (VA), demonstrating the company's strategic position as a key technology provider for federal scientific and diagnostic research initiatives.
Description
01-novaseq x series 10B reagent kit (100 cycle) 02-novaseq x series 1.5B reagent kit (100 CYC) 03-nextseq 2000 P4 xleapsbs reagent kit (200 cycles) 04-nextseq 2000 P4 xleapsbs reagent kit (100 cycles) 05-illumina DNA PCR-free prep, tagmentation
Quick answers
Who was awarded contract 75N92B25F20013?
75N92B25F20013 was awarded to Illumina, Inc. by National Insititue of Arthritis and Musculoskeletal and Skin Diseases (National Institutes of Health) on August 22, 2025.
How much is contract 75N92B25F20013 worth?
The government has obligated $98,243 on 75N92B25F20013.
Is contract 75N92B25F20013 an order under another contract?
Yes. 75N92B25F20013 is a delivery order under 75N92020D00022, an indefinite delivery contract.
Was contract 75N92B25F20013 competed?
The extent of competition for 75N92B25F20013 was not competed.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award